Arming antibodies for cancer therapy

被引：66

作者：

Polakis, P ^{[1
]}

机构：

[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA

来源：

CURRENT OPINION IN PHARMACOLOGY | 2005年 / 5卷 / 04期

关键词：

D O I：

10.1016/j.coph.2005.04.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Specifying the delivery of a highly toxic agent to cancers while sparing normal tissue is an attractive prospect for the treatment of cancer. Cell surface antigens with highly restricted expression patterns have been identified and the means by which cytotoxic agents are appended to antibodies has been greatly refined. Myriad formulations involving radionuclides, bacterial toxins and small-molecule drugs linked to antibodies through peptides, protein fusions and chelating agents are in preclinical and clinical evaluation, and a few have been approved as human medicines. Recent advances hold promise for improving the therapeutic index of these anti-cancer drugs.

引用

页码：382 / 387

页数：6

共 58 条

[11] Bioinformatics and cancer target discovery [J].

Desany, B ;

Zhang, ZM .

DRUG DISCOVERY TODAY, 2004, 9 (18) :795-802

[12]

Di Paolo C, 2003, CLIN CANCER RES, V9, P2837

[13] Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J].

Doronina, SO ;

Toki, BE ;

Torgov, MY ;

Mendelsohn, BA ;

Cerveny, CG ;

Chace, DF ;

DeBlanc, RL ;

Gearing, RP ;

Bovee, TD ;

Siegall, CB ;

Francisco, JA ;

Wahl, AF ;

Meyer, DL ;

Senter, PD .

NATURE BIOTECHNOLOGY, 2003, 21 (07) :778-784

[14] Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages [J].

Dubowchik, GM ;

Radia, S ;

Mastalerz, H ;

Walker, MA ;

Firestone, RA ;

King, HD ;

Hofstead, SJ ;

Willner, D ;

Lasch, SJ ;

Trail, PA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (11) :1529-1532

[15] Recombinant immunotoxins for treating cancer [J].

FitzGerald, DJ ;

Kreitman, R ;

Wilson, W ;

Squires, D ;

Pastan, I .

INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 293 (7-8) :577-582

[16] cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J].

Francisco, JA ;

Cerveny, CG ;

Meyer, DL ;

Mixan, BJ ;

Klussman, K ;

Chace, DF ;

Rejniak, SX ;

Gordon, KA ;

DeBlanc, R ;

Toki, BE ;

Law, CL ;

Doronina, SO ;

Siegall, CB ;

Senter, PD ;

Wahl, AF .

BLOOD, 2003, 102 (04) :1458-1465

[17]

GALSKY MD, 2004, J CLIN ONCOL, P22

[18] Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia [J].

Giles, F ;

Estey, E ;

O'Brien, S .

CANCER, 2003, 98 (10) :2095-2104

[19]

GREENFIELD RS, 1990, CANCER RES, V50, P6600

[20] A MONOCLONAL-ANTIBODY REACTIVE WITH NORMAL AND LEUKEMIC HUMAN MYELOID PROGENITOR CELLS [J].

GRIFFIN, JD ;

LINCH, D ;

SABBATH, K ;

LARCOM, P ;

SCHLOSSMAN, SF .

LEUKEMIA RESEARCH, 1984, 8 (04) :521-534

← 1 2 3 4 5 6 →